This initiative originated from the General Directorate of Public Health in Galicia (Payer).
The player wants to publish in the media that they are engaging in risk-sharing agreements and report the results.
Therefore, the solution may include the Simulator + ARA for this specific agreement, as the payer is interested in making the results of this project visible to the press.
Sanofi Spain — wants to meet the payer's expectations but does not want to take on risks and wants assurance that it will be successful.
Sanofi Global — The budget for this project comes from Sanofi Global, and it appears they do not have financial constraints.
Framing - Sanofi / Lyfegen @David @All
What Sanofi wants from Lyfegen?
Avoid risks. Raise their profile in Galicia and media.
Lyfegen means Peace of mind. To have the assurance we will guide them through every step of the way and have solution for all the risks.
Predictability: Lib / Sim / ARA the assurance that Galicia will accept, and that Sanofi will not risk money. ****Simulator provides a preview of the impact for Sanofi.
Success of Negotiation: By having several scenarios, Sanofi do not play everything on a single card.
Raising profile for Galicia thanks to Lyfegen : Detailed offer Specific Metrics
A comprehensive solution - Integral solution of all Sanofi's needs with a single company.
We cover knowledge (we reduce reputational risk of Galicia not trusting or counter-offering).
We frame the debate - We cover the scenarios (reduce risk of Galicia changing conditions.
Follow-up (ARA)
1. Library @Simona Belmonte
They have access asking Birgit Holz, but we don’t want to give them access right away.
First we want:
Goal:
Understand their objective to guide them how to use it
Make a success story out of it
Gives us validation to extend the license
What Sanofi said they want in Lyfegen Library (expressed Need)
Context:
They have to develop an OBA for Vaccine:
Lack of experience about OBA in general.
Lack of knowledge of similar cases.
Look for Samples.
Concern for Risks
They want to be look as experts presenting a project that will please the Galician requirement, without making them look bad.
Sanofi Questions:
Is there any risk-sharing agreement on Vaccines.
Was it successful / Any potential controversy? / Did the agreement went well? Was it changed after no much time?
Agreement model?
Outcome variable? What metrics were used?
Specific question: They mentioned there could be a previous risk-sharing agreements for Efluelda in Denmark (and other Vaccines with OBAs)
2. Simulator @Antti
Efluelda
Current Status: Pilot project: The current age threshold is 80+.
Objective: The project would be lowering it to 70+ / 65+ Establishing outcome-based payment models backed by evidence.
Questions:
What would be the impact if the age of the population to be vaccinated changes.
Current Price of Efluelda (in competition):
€25. Price of alternatives: adjuvanted vaccine €13; standard dose vaccines €3-5.
Prevalence:
to be applied in the population aged 60-79 years in Galicia (660,000 people according to INE).
The vaccination coverage rate in the 65-74 year-old population is 67%.
Metrics to be considered for ARC/P4P:
Still assessing which outcome measures to use
cases
Hospitalisations
deaths averted
vs. use of standard vaccine
population-based, not individual implementation; multi-year agreement (3-4 years)
3. Lyfegen / Sanofi Global @David @Nico (Just In Case)
Solve Questions about Sanofi Global / Lyfegen Relationship
Mention Birgit Holz
Ask Global for Library / Ask Global and-or for the Budget for Lyfegen Simulator-ARA
Budget
The budget for this project comes from Sanofi Global, and it appears they do not have financial constraints.
Question - Is ther leftover budget in this project or in Sanofi Spain that could be allocated for Lyfegen’s collaboration?
Contexto General @Todos
¿Por qué está sucediendo esto en Galicia?
Esta iniciativa se originó en la Dirección General de Salud Pública de Galicia (Pagador).
El actor quiere publicar en los medios que están participando en acuerdos de riesgo compartido e informar sobre los resultados.
Por lo tanto, la solución puede incluir el Simulador + ARA para este acuerdo específico, ya que el pagador está interesado en hacer visibles los resultados de este proyecto a la prensa.
Sanofi España — quiere cumplir con las expectativas del pagador pero no quiere asumir riesgos y desea garantías de que tendrá éxito.
Sanofi Global — El presupuesto para este proyecto proviene de Sanofi Global, y parece que no tienen limitaciones financieras.
Marco - Sanofi / Lyfegen @David @Todos
¿Qué quiere Sanofi de Lyfegen?
Evitar riesgos. Aumentar su perfil en Galicia y en los medios.
Lyfegen significa Tranquilidad. Tener la seguridad de que los guiaremos en cada paso del camino y tendremos solución para todos los riesgos.
Previsibilidad: Lib / Sim / ARA la garantía de que Galicia aceptará, y que Sanofi no arriesgará dinero. ****El Simulador proporciona una vista previa del impacto para Sanofi.
Éxito de la Negociación: Al tener varios escenarios, Sanofi no se juega todo a una sola carta.
Elevar el perfil de Galicia gracias a Lyfegen : Oferta detallada Métricas específicas
Una solución integral - Solución integral de todas las necesidades de Sanofi con una sola empresa.
Cubrimos el conocimiento (reducimos el riesgo reputacional de que Galicia no confíe o haga una contraoferta).
Enmarcamos el debate - Cubrimos los escenarios (reducimos el riesgo de que Galicia cambie las condiciones).
Seguimiento (ARA)
1. Biblioteca @Simona Belmonte
Tienen acceso preguntando a Birgit Holz, pero no queremos darles acceso de inmediato.
Primero queremos:
Objetivo:
Entender su objetivo para guiarlos en cómo usarla
Hacer una historia de éxito de ello
Nos da validación para extender la licencia
Lo que Sanofi dijo que quiere en la Biblioteca Lyfegen (Necesidad expresada)
2. Simulador @Antti
Efluelda
Estado Actual: Proyecto piloto: El umbral de edad actual es de 80+.
Objetivo: El proyecto sería bajarlo a 70+ / 65+ Estableciendo modelos de pago basados en resultados respaldados por evidencia.
Preguntas:
Precio Actual de Efluelda (en competencia):
Prevalencia:
Métricas a considerar para ARC/P4P:
Aún evaluando qué medidas de resultado utilizar
3. Lyfegen / Sanofi Global @David @Nico (Por Si Acaso)
Resolver Preguntas sobre la Relación Sanofi Global / Lyfegen